By a GenomeWeb staff reporter
By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Beckman Coulter's president has issued a letter to employees informing them that 8 percent of the company's workforce will be laid off as part of the company's restructuring.
By Bernadette TonerThis article was originally published Aug. 19.
The companies have reached a settlement in an intellectual property lawsuit related to technology for isolating and purifying nucleic acids.
During a conference call, Danaher's CEO said that although issues surrounding broad quality systems at Beckman Coulter, as well issues with FDA are improving, there "is plenty of work ahead of us."
Thomas Schinecker, Kip Miller, Kevin McKernan
Beckman Coulter Genomics Target Capture Sequencing Service; Illumina TruSeq Custom Enrichment; Ion Torrent Barcoding, Library Quantitation, Ion Sphere Control Kits
Beckman Coulter announced changes to its board, Steven Salzberg moves to Johns Hopkins, Complete Genomics names a new senior vice president and chief commercial officer, and more.
The tender offer period finished with around 92 percent of Beckman Coulter shareholders tendering their shares.
Danaher commenced a subsequent offering period set to expire on June 29, after which it expects to complete its purchase of Beckman Coulter.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.